AML1/ETO Oncoprotein is Directed to AML1 Binding Regions and Co-localizes with AML1 and HEB on Its Targets

Overview

Journal PLoS Genet

Specialty Genetics

Date 2008 Dec 2

PMID 19043539

Citations 43

Authors

Alessandro Gardini

Matteo Cesaroni

Lucilla Luzi

Akiko J Okumura

Joseph R Biggs

Simone P Minardi

Elisa Venturini

Dong-Er Zhang

Pier Giuseppe Pelicci

Myriam Alcalay

Affiliations

Soon will be listed here.

Abstract

A reciprocal translocation involving chromosomes 8 and 21 generates the AML1/ETO oncogenic transcription factor that initiates acute myeloid leukemia by recruiting co-repressor complexes to DNA. AML1/ETO interferes with the function of its wild-type counterpart, AML1, by directly targeting AML1 binding sites. However, transcriptional regulation determined by AML1/ETO probably relies on a more complex network, since the fusion protein has been shown to interact with a number of other transcription factors, in particular E-proteins, and may therefore target other sites on DNA. Genome-wide chromatin immunoprecipitation and expression profiling were exploited to identify AML1/ETO-dependent transcriptional regulation. AML1/ETO was found to co-localize with AML1, demonstrating that the fusion protein follows the binding pattern of the wild-type protein but does not function primarily by displacing it. The DNA binding profile of the E-protein HEB was grossly rearranged upon expression of AML1/ETO, and the fusion protein was found to co-localize with both AML1 and HEB on many of its regulated targets. Furthermore, the level of HEB protein was increased in both primary cells and cell lines expressing AML1/ETO. Our results suggest a major role for the functional interaction of AML1/ETO with AML1 and HEB in transcriptional regulation determined by the fusion protein.

Citing Articles

Nanoparticle-mediated targeting of the fusion gene RUNX1/ETO in t(8;21)-positive acute myeloid leukaemia.

Issa H, Swart L, Rasouli M, Ashtiani M, Nakjang S, Jyotsana N Leukemia. 2023; 37(4):820-834.

PMID: 36823395 PMC: 10079536. DOI: 10.1038/s41375-023-01854-8.

LYL1 facilitates AETFC assembly and gene activation by recruiting CARM1 in t(8;21) AML.

Chen Q, Cevher M, Jiang Q, Wang S, Sun X, Roeder R Proc Natl Acad Sci U S A. 2022; 119(42):e2213718119.

PMID: 36215477 PMC: 9586329. DOI: 10.1073/pnas.2213718119.

Mitochondria and Their Relationship with Common Genetic Abnormalities in Hematologic Malignancies.

Czegle I, Gray A, Wang M, Liu Y, Wang J, Wappler-Guzzetta E Life (Basel). 2021; 11(12).

PMID: 34947882 PMC: 8707674. DOI: 10.3390/life11121351.

Zinc finger protein ZNF384 is an adaptor of Ku to DNA during classical non-homologous end-joining.

Singh J, Smith R, Rother M, de Groot A, Wiegant W, Vreeken K Nat Commun. 2021; 12(1):6560.

PMID: 34772923 PMC: 8589989. DOI: 10.1038/s41467-021-26691-0.

AML1/ETO and its function as a regulator of gene transcription via epigenetic mechanisms.

Rejeski K, Duque-Afonso J, Lubbert M Oncogene. 2021; 40(38):5665-5676.

PMID: 34331016 PMC: 8460439. DOI: 10.1038/s41388-021-01952-w.

References

Cameron E, Neil J . The Runx genes: lineage-specific oncogenes and tumor suppressors. Oncogene. 2004; 23(24):4308-14. DOI: 10.1038/sj.onc.1207130. View

ONeil J, Shank J, Cusson N, Murre C, Kelliher M . TAL1/SCL induces leukemia by inhibiting the transcriptional activity of E47/HEB. Cancer Cell. 2004; 5(6):587-96. DOI: 10.1016/j.ccr.2004.05.023. View

Uchida H, Zhang J, Nimer S . AML1A and AML1B can transactivate the human IL-3 promoter. J Immunol. 1997; 158(5):2251-8. View

Rhoades K, Hetherington C, Rowley J, Hiebert S, Nucifora G, Tenen D . Synergistic up-regulation of the myeloid-specific promoter for the macrophage colony-stimulating factor receptor by AML1 and the t(8;21) fusion protein may contribute to leukemogenesis. Proc Natl Acad Sci U S A. 1996; 93(21):11895-900. PMC: 38155. DOI: 10.1073/pnas.93.21.11895. View

Mulloy J, Jankovic V, Wunderlich M, Delwel R, Cammenga J, Krejci O . AML1-ETO fusion protein up-regulates TRKA mRNA expression in human CD34+ cells, allowing nerve growth factor-induced expansion. Proc Natl Acad Sci U S A. 2005; 102(11):4016-21. PMC: 554792. DOI: 10.1073/pnas.0404701102. View

Finocchiaro G, Parise P, Minardi S, Alcalay M, Muller H . GenePicker: replicate analysis of Affymetrix gene expression microarrays. Bioinformatics. 2004; 20(18):3670-2. DOI: 10.1093/bioinformatics/bth416. View

Dennis Jr G, Sherman B, Hosack D, Yang J, Gao W, Lane H . DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003; 4(5):P3. View

Shimizu K, Kitabayashi I, Kamada N, Abe T, Maseki N, Suzukawa K . AML1-MTG8 leukemic protein induces the expression of granulocyte colony-stimulating factor (G-CSF) receptor through the up-regulation of CCAAT/enhancer binding protein epsilon. Blood. 2000; 96(1):288-96. View

Frank R, Zhang J, Uchida H, Meyers S, Hiebert S, Nimer S . The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B. Oncogene. 1995; 11(12):2667-74. View

10.

Davis J, McGhee L, Meyers S . The ETO (MTG8) gene family. Gene. 2003; 303:1-10. DOI: 10.1016/s0378-1119(02)01172-1. View

11.

Kim T, Barrera L, Zheng M, Qu C, Singer M, Richmond T . A high-resolution map of active promoters in the human genome. Nature. 2005; 436(7052):876-80. PMC: 1895599. DOI: 10.1038/nature03877. View

12.

Alcalay M, Meani N, Gelmetti V, Fantozzi A, Fagioli M, Orleth A . Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair. J Clin Invest. 2003; 112(11):1751-61. PMC: 281638. DOI: 10.1172/JCI17595. View

13.

Yan M, Kanbe E, Peterson L, Boyapati A, Miao Y, Wang Y . A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis. Nat Med. 2006; 12(8):945-9. DOI: 10.1038/nm1443. View

14.

Meani N, Minardi S, Licciulli S, Gelmetti V, Lo Coco F, Nervi C . Molecular signature of retinoic acid treatment in acute promyelocytic leukemia. Oncogene. 2005; 24(20):3358-68. DOI: 10.1038/sj.onc.1208498. View

15.

Okuda T, Cai Z, Yang S, Lenny N, Lyu C, Van Deursen J . Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. Blood. 1998; 91(9):3134-43. View

16.

Klampfer L, Zhang J, Zelenetz A, Uchida H, Nimer S . The AML1/ETO fusion protein activates transcription of BCL-2. Proc Natl Acad Sci U S A. 1996; 93(24):14059-64. PMC: 19494. DOI: 10.1073/pnas.93.24.14059. View

17.

Matozaki S, Nakagawa T, Kawaguchi R, Aozaki R, Tsutsumi M, Murayama T . Establishment of a myeloid leukaemic cell line (SKNO-1) from a patient with t(8;21) who acquired monosomy 17 during disease progression. Br J Haematol. 1995; 89(4):805-11. DOI: 10.1111/j.1365-2141.1995.tb08418.x. View

18.

Frank S, Schroeder M, Fernandez P, Taubert S, Amati B . Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activation. Genes Dev. 2001; 15(16):2069-82. PMC: 312758. DOI: 10.1101/gad.906601. View

19.

Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A . Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med. 2004; 11(1):71-6. DOI: 10.1038/nm1160. View

20.

Peterson L, Yan M, Zhang D . The p21Waf1 pathway is involved in blocking leukemogenesis by the t(8;21) fusion protein AML1-ETO. Blood. 2007; 109(10):4392-8. PMC: 1885483. DOI: 10.1182/blood-2006-03-012575. View